Cash Distribution - PermRock Royalty Trust announced a cash distribution of $289,632.56, equating to $0.023807 per Trust Unit, based on production during February 2025[7] - The cash distribution is payable on May 14, 2025, to record holders as of April 30, 2025[7]

Under the Purchase and Sale and Agreement, (a) the Grantors sold and conveyed to the Buyer all of the Grantors' right, title and interest in and to the Underlying Properties (which shall remain burdened by the net profits interest and subject to the Conveyance of Net Profits Interest, dated May 4, 2018, by and among the Grantors, Simmons Bank (as trustee of the Trust, succeeded by Argent Trust Company) and Wilmington Trust, National Association); and (b) Boaz Energy sold and conveyed to Ustx LLC, a Delaware ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38472 PERMROCK ROYALTY TRUST (Exact name of registrant as specified in its charter) Delaware 82-67251 ...

Cash Distribution - PermRock Royalty Trust announced a cash distribution of $489,995.26, equating to $0.040276 per Trust Unit, based on production during November 2024[6] - The cash distribution is payable on February 14, 2025, to record holders as of January 31, 2025[6]

Transaction Overview - Boaz Energy and its affiliate Boaz Royalty entered into a Purchase and Sale Agreement with T2S Permian Acquisition II LLC on January 10, 2025, regarding the sale of the Underlying Properties and 4,884,861 Boaz Trust Units [4] - The Underlying Properties are subject to the Net Profits Interest conveyed to the Trust, which grants the Trust the right to receive 80% of the net profits from oil and natural gas production [4][5] Transaction Details - The Grantors will sell and convey to the Buyer all of Boaz Energy's right, title, and interest in the Underlying Properties, which remain burdened by the Net Profits Interest and subject to the Conveyance [1] - The transaction includes the sale of 4,884,861 Boaz Trust Units representing beneficial interests in the Trust [1] - The Closing is anticipated to occur in March 2025, subject to customary closing conditions being satisfied [2] Post-Transaction Operations - From and after the Closing, the Buyer will own the Underlying Properties and the Boaz Trust Units, and the Buyer (or an affiliate) will become the operator of the Underlying Properties [2] - Boaz Energy will facilitate the transfer of operations of the Underlying Properties from Boaz Energy to the Buyer [3] - Argent Trust Company, as trustee of the Trust, expects to continue the administration of the Trust in the ordinary course of business [3] Company Background - PermRock Royalty Trust is a Delaware statutory trust formed to own a net profits interest representing the right to receive 80% of the net profits from the sale of oil and natural gas production from the Underlying Properties [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 001-38472 82-6725102 (State or Other Jurisdiction of Incorporation)(Commission File Number) (IRS Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Units of Beneficial Interest PRT New York Stock Exchange FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 21, 2024 PERMROCK ROYALTY TRUST (Exact name of Re ...

• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy • Prelude plans to seek a partner for future development of PRT2527 in hematologic malignancies WILMINGTON, Del., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the presentation of the first interim clinical data from its ongoing open-label ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 001-38472 82-6725102 (State or Other Jurisdiction of Incorporation)(Commission File Number) (IRS Employer Identification No.) Argent Trust Company, Trustee 3838 Oak Lawn Ave. Suite 1720 Dallas, Texas 75219 (Address of Principal Executive Offices) (Zip Code) Title of each class Trading Symbol(s) Name of each exchange on which registered Units of Beneficial Interest PRT New York Stock Exchange FORM 8-K CURRENT REPORT Pursuant to ...

- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4- mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation - At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drugrelated serious adverse events - Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) - ...

Core Viewpoint - Prelude Therapeutics has entered into a collaboration with Merck to conduct a Phase 2 clinical trial evaluating the combination of its investigational SMARCA2 degrader, PRT3789, with Merck's anti-PD-1 therapy, KEYTRUDA, targeting patients with SMARCA4-mutated cancers [2][4][7]. Group 1: Clinical Development - PRT3789 is a first-in-class, highly selective SMARCA2 degrader currently in Phase 1 clinical development, focusing on biomarker-selected SMARCA4 mutant patients [3][11]. - The Phase 1 study aims to establish the safety and tolerability of PRT3789, evaluate its activity, pharmacokinetics, and pharmacodynamics, and determine a recommended Phase 2 dose [3][11]. - Enrollment for the Phase 1 trial is on track, with expectations to conclude monotherapy dose escalation by mid-2024 [3]. Group 2: Collaboration Details - Under the collaboration agreement, Merck will supply KEYTRUDA for the Phase 2 trial, while Prelude will act as the trial sponsor [4][12]. - Both companies retain all commercial rights to their respective compounds, whether used alone or in combination [4]. Group 3: Mechanistic Rationale - The combination of the SMARCA2 degrader and anti-PD-1 therapy is supported by pre-clinical data, which indicates enhanced anti-tumor immunity and tumor regressions in SMARCA4-mutated cancers [8]. - The rationale for this combination was previously presented at the 2023 AACR International Conference on Molecular Targets and Cancer Therapeutics [8]. Group 4: Company Overview - Prelude Therapeutics is focused on developing innovative drug candidates targeting critical cancer cell pathways, with a pipeline that includes PRT3789, a CDK9 inhibitor (PRT2527), and a next-generation CDK4/6 inhibitor (PRT3645) [11]. - The company is also collaborating with AbCellera to discover and develop next-generation antibody drug conjugate products [11].